RCKT earnings date and last-quarter result: next report 2026-08-06, last quarter miss, P/E -1.76. Updated 2026-07-23.
Rocket Pharmaceuticals (RCKT) Research Hub
Rocket Pharmaceuticals (RCKT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.28 USD (-0.44%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.76, market cap 0.37B. This hub links to the full technical, earnings and options research available for RCKT.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.28 USD (-0.44%) |
| 52-week range | 2.17 USD – 4.33 USD |
| Trend regime | Range |
| 14-day RSI | 42.5 (Bearish) |
| Trailing P/E | -1.76 |
| Market cap | 0.37B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for RCKT
Covered Call on RCKT: how it works, illustrative setup around the real 2.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RCKT: how it works, illustrative setup around the real 2.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RCKT: how it works, illustrative setup around the real 2.28 USD price, max profit/loss, breakeven and when to use it. Educational.
RCKT technical analysis: range, last 2.28 USD, RSI 42.5, 52w range 2.17 USD–4.33 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RCKT in?
Rocket Pharmaceuticals (RCKT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RCKT in an uptrend or downtrend?
As of 2026-10-26, RCKT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RCKT's trailing P/E ratio?
RCKT's trailing P/E is -1.76, with a market cap of 0.37B. See the earnings research page for full valuation detail.
When does RCKT next report earnings?
RCKT is next scheduled to report earnings on 2026-08-06.